clopidogrel
美 
英
例句
Conclusion The PPI esomeprazole has no significant influence on inhibition of platelet aggregation by clopidogrel.
结论未发现埃索美拉唑对氯吡格雷的抗血小板聚集作用产生明显影响。
The invention relates to a bisulfate clopidogrel solid preparation, particles and a preparation method thereof.
本发明涉及一种硫酸氢氯吡格雷的固体制剂、其颗粒及其制备方法。
The difference was primarily due to a reduction in the rate of stroke with clopidogrel.
两组间差异主要源于使用氯吡格雷减低中风发生率。
Patients assigned the clopidogrel loading dose had slightly less platelet reactivity, but it was not significant compared with placebo.
应用负荷剂量氯吡格雷的患者血小板活性稍小，但是和安慰剂组比较没有明显差别。
Secondly, for those patients who do not undergo PCI, the standard dose regimen of clopidogrel is sufficient.
其次，对那些未行PCI的患者，标准剂量给药方案已经足够；
Cigarette smoking induces CYP1A2 and may, therefore, enhance the conversion of clopidogrel to its active metabolite.
吸烟诱导CYP1A2而且可能因此增强氯吡格雷转化为其活性代谢产物。
Objectives: We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective.
目的：我们假设门诊病人标准化氯吡格雷脱敏疗法是安全且有效的。
Patients undergoing stent-based PCI should be treated with triple therapy consisting of aspirin, clopidogrel, and warfarin.
植入支架的PCI患者应该应用阿司匹林、氯吡格雷和华法林三联治疗。
Experiment results show that the stability of the clopidogrel bisulfate tablet of the invention is excellent.
实验表明，本发明的硫酸氢氯吡格雷片剂的稳定性优异。
The combination of aspirin plus clopidogrel is not more effective than clopidogrel alone, but carries a higher bleeding risk.
阿司匹林与氯吡咯雷联合应用疗效不优于氯吡咯雷单独用药，但却有更高的出血风险。
Background: Clopidogrel is an anti-platelet agent which causes an increase in bleeding time.
背景：氯吡格雷是一种导致凝血时间延长的抗血小板药物。
The rates of adverse cardiovascular events were lowest in patients treated with both clopidogrel and enoxaparin, the investigators report.
并且同时应用氯吡格雷和依诺肝素的患者心血管事件的发生率最低。
Recent mechanistic studies, however, suggest that omeprazole may reduce the inhibitory effect of clopidogrel on platelet aggregation.
然而已有机制研究提出奥美拉唑会降低氯吡格雷抗血小板的疗效。
Clopidogrel therapy does have implications for peri-operative blood loss, but hip fracture is a complex and multifactorial condition.
氯吡格雷疗法确实与围手术期的失血有所关联，但髋部骨折是一种复杂多因素的情况。
Clopidogrel is not superior to aspirin in unselected stroke patients but is superior in patients at high risk of recurrence.
氯吡格雷在非选择性卒中患者方面不优于阿司匹林，但对于卒中复发率高的患者更有效。
As demonstrated, the combination of aspirin, clopidogrel and oral anticoagulants increase three to five-fold the hemorrhagic risk.
联合使用阿司匹林、氯吡格雷和口服抗凝药使出血的风险增加3~5倍。
Long-term clopidogrel therapy after percutaneous coronary intervention: the "Emperors New Clothes"
经皮冠状动脉介入治疗后氯吡格雷长期治疗：“皇帝的新装”
Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.
长期与氯吡格雷抗血小板治疗是强制性植入后药物涂层支架。
Patients with clopidogrel resistance had high platelet aggregation and were apt to suffer from cardiovascular events.
氯吡格雷抵抗者血小板聚集率高，易发生心血管事件。
Objective To investigate the therapeutic effect of clopidogrel on progressive ischemic cerebral apoplexy.
目的研究氯吡格雷治疗进展型缺血性脑卒中的疗效。
Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.
目的观察质子泵抑制剂埃索美拉唑是否影响氯吡格雷的抗血小板聚集作用。
Objective: To assess the PPB rate and outcome and identify risk factors associated with PPB in patients taking clopidogrel.
目的：评估服用氯吡格雷病人PPB的发生率，结果以及相关的危险因素。
Clopidogrel is a newer, more expensive, alternative to aspirin which may be used in some patients intolerant of aspirin.
克拉匹多是一种新药，价格更贵，可用来作为对阿斯匹林过敏病人的替代品。
A brief overview of drug interaction as a risk factor for clopidogrel resistance is given.
简要概述了药物相互作用的风险因素，给出氯吡格雷抵抗。
Objective To explore the effect of clopidogrel bisulfate on aspirin resistance (AR) in patients with ischemic cerebrovascular disease.
目的观察氯吡格雷对缺血性脑血管病患者阿司匹林抵抗（AR）的影响。
One disabling or fatal stroke would be prevented for every approximately 200 patients treated for 1 year with clopidogrel added to aspirin.
对200名病人进行为期一年的氯吡格雷加阿司匹林联合治疗大约可以预防一起致残或致死性卒中的发生。
The invention also provides a preparation method of the clopidogrel bisulfate tablet.
本发明还提供了所述的硫酸氢氯吡格雷片剂的制备方法。
Background: Response variability to clopidogrel therapy has been demonstrated.
背景：已有研究显示氯吡格雷治疗反应的变异性。
The incidence of clopidogrel resistance was evaluated by the percent reduction of PAGM.
根据PAGM降低程度判断氯吡格雷抵抗发生率。
Preferred drugs in the order: first choice as clopidogrel, to aspirin second choice, third choice as ticlopidine.
优选药物的次序为：第一选择为氯吡格雷，第二选择为阿司匹林，第三选择为噻氯匹啶。
In this article, we reviewed the efficacy and security of high-loading-dose of Clopidogrel in Acute Coronary Syndrome.
现就应用高负荷剂量氯吡格雷治疗急性冠状动脉综合征的有效性和安全性进行综述。
abstract: Objective To observe the low molecular weight heparin and aspirin and clopidogrel treatment of unstable angina pectoris.
目的观察氯吡格雷联合低分子肝素和阿斯匹林治疗不稳定型心绞痛的疗效。
What is the relationship between clopidogrel resistance and cardiovascular outcome?
氯吡格雷抵抗和心血管结果之间有何关联？
Background: No data exist about the impact of non responsiveness to clopidogrel on the risk of DES thrombosis.
背景：没有数据说明关于氯吡格雷无效对药物洗脱支架血栓形成风险的影响。
But in clinical practice, many patients take aspirin, clopidogrel or warfarin together to prevent blood clots.
但是临床中许多患者需要同时服用阿司匹林、氯吡格雷、华法林等抗凝药物预防血栓形成。
Clopidogrel is metabolically activated by several hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2.
氯吡格雷通过肝脏细胞色素P450（CYP）酶——包括CYP1A2——代谢性激活。
So clopidogrel could be doubly beneficial, he says.
他说，因此氯吡格雷的益处可能也是双重性的。
According to the above results of optimization, the overall yield of clopidogrel hydrogen sulfate is 39%.
采用上述最佳工艺条件，氯吡格雷硫酸氢盐的总收率为39%。
I think the issue of clopidogrel resistance is real and it matters, and this drug is a major advance in that regard.
顾问小组成员理查德•卡农博士说，“我认为氯吡格雷抵抗的观点是真实且紧要的，并且此药物是在关注下取得的重要进展。”
Study Question: What is the evidence that a platelet rebound exists, and can it be attenuated by clopidogrel tapering?
研究问题：血小板反跳存在的证据是什么？它能通过氯吡格雷逐渐停药而减弱呢？
